Skip to main content
CAPRICOR THERAPEUTICS, INC. logo

CAPRICOR THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · CAPR ISIN · US14070B3096 LEI · 5493002ZI5PDLXV4DX14 US Manufacturing
Open in API
Filings indexed 919 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US CAPR

About CAPRICOR THERAPEUTICS, INC.

https://capricor.com/

Capricor Therapeutics is a clinical-stage biotechnology company focused on the development of biologics, primarily cell and exosome-based technologies. The company's science is centered on its proprietary platform of allogeneic cardiosphere-derived cells (CDCs) and engineered exosomes to create novel therapeutics. Its lead candidate, Deramiocel (CAP-1002), is a cell therapy that has completed a pivotal Phase 3 study for the treatment of Duchenne muscular dystrophy (DMD). Capricor's pipeline leverages its core technologies to treat or prevent a broad range of serious diseases with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
ARS - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
Annual Report
2026-04-10 English
DEF 14A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
Proxy Solicitation & Information Statement
2026-04-10 English
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
Director's Dealing
2026-03-28 English
S-8 Filing
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Capricor Therapeutics, Inc. It registers shares issuable under an equity incentive plan. The text includes references to incorporation by reference of other filings such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, but this document itself is a registration statement for securities under the Securities Act of 1933, specifically Form S-8. Form S-8 is used for registering securities to be offered to employees under employee benefit plans and is not an annual report, earnings release, or other financial report. It is a capital market filing related to equity incentive plans and share registration. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes, including registration statements for equity plans.
2026-01-30 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-01-26 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.